comparemela.com

Latest Breaking News On - Aerovate therapeutics - Page 1 : comparemela.com

Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 3.6%

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) shot up 3.6% during mid-day trading on Thursday . The company traded as high as $24.05 and last traded at $23.86. 59,742 shares traded hands during trading, a decline of 62% from the average session volume of 159,164 shares. The stock had previously closed at $23.02. Wall […]

United-states
Switzerland
Swiss
Timothyp-noyes
Marinus-verwijs
Aerovate-therapeutics-inc
Wells-fargo-company
Jefferies-financial-group
Ikarian-capital
Securities-exchange-commission
Aerovate-therapeutics-company-profile
Vanguard-group-inc

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Short Interest Up 16.5% in May

Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Free Report) saw a significant increase in short interest during the month of May. As of May 15th, there was short interest totalling 2,190,000 shares, an increase of 16.5% from the April 30th total of 1,880,000 shares. Based on an average daily trading volume, of 167,500 shares, the short-interest […]

Switzerland
Alps
Switzerland-general
United-states
Swiss
Benjamint-dake
Georgea-eldridge
Aerovate-therapeutics-inc
Eventide-asset-management
Alps-advisors-inc
Securities-exchange-commission

Aerovate Therapeutics : June 2024 Corporate Presentation

Aerovate Therapeutics (NASDAQ:AVTE) Stock Rating Reaffirmed by Wedbush

Wedbush reiterated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has a $41.00 price target on the stock. Other analysts also recently issued reports about the stock. Jefferies Financial Group initiated coverage on shares of Aerovate Therapeutics in […]

Alps
Switzerland-general
Switzerland
United-states
Swiss
Hunter-gillies
Georgea-eldridge
Silverarc-capital-management
Securities-exchange-commission
Nasdaq
Aerovate-therapeutics-inc
Alps-advisors-inc

Wedbush Reiterates "Outperform" Rating for Aerovate Therapeutics (NASDAQ:AVTE)

Wedbush restated their outperform rating on shares of Aerovate Therapeutics (NASDAQ:AVTE – Free Report) in a research report report published on Wednesday, Benzinga reports. The brokerage currently has a $41.00 price target on the stock. AVTE has been the subject of a number of other reports. Wells Fargo & Company reissued an overweight rating and […]

United-states
Georgea-eldridge
Hunter-gillies
Eventide-asset-management
Jefferies-financial-group
Ikarian-capital
Nasdaq
Aerovate-therapeutics-inc
Wells-fargo-company
Vanguard-group-inc
Alps-advisors-inc
Aerovate-therapeutics

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.